Most importantly, clinical trials with RHAMM peptide vaccination have already demonstrated immunological and clinical responses in patients with various hematological malignancies, including AML, chronic lymphocytic leukemia, multiple myeloma and myelodysplastic syndrome [20–22]. Here, HMMR is linked to hematologic disorder.